Company PresentationOctober, 2017 Ofer Haviv, President & CEO

Safe Harbor Statement 2 This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, “Evogene” or “we”), that are considered “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Such forward-looking statements may be identified by the use of such words as “believe,” “expect,” “anticipate,” “should,” “planned,” “estimated,” “intend” and “potential” or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading “Risk Factors.” All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions. The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

What We Do 3 We develop novel products for life- science markets… …through the use of a unique computational predictive biology platform

About Us 4 Evogene is a leading company for the development of novel products for life science markets through the use of a unique computational predictive biology (CPB) platformToday, focused on developing products in three fields in the Ag world: Seeds, Ag- Biologicals and Ag-ChemicalsTwo subsidiaries: Evofuel (100%) - Castor Seeds and Biomica (90%) - Human MicrobiomeStrategic collaborations over the years with world-leading companies such as BASF, Bayer, DuPont-Pioneer, Monsanto, Syngenta and ICLRevenue stream: (i) R&D payments, (ii) milestone payments (iii) royalties from product salesAn updated strategy was defined - consists of shorter time to market and more downstream activitiesAdditional Facts:Located in Rehovot, Israel and St. Louis, Missouri, US~160 employees, ~ 50 PhDs Traded on NASDAQ and TASE, covered by Credit Suisse and Piper JaffrayCash position: ~80 million USD as of June 30th , 2017; no debt

Evogene – An Evolving Story 5 Seed TraitsYield & ABSTPlant Disease 2007 - 2013 IPO TASE - IPO NYSE EvofuelCastor Seeds (100%)

Evogene – An Evolving Story 6 Ag ChemicalsHerbicides Ag BiologicalsBio stimulants Seed TraitsYield & ABSTPlant DiseaseInsect Control 2013 - 2017 IPO NYSE – Sep 2017 EvofuelCastor Seeds (100%)

Evogene – An Evolving Story 7 2017 - Onward Ag ChemicalsHerbicidesInsecticides Ag BiologicalsBio stimulantsBio Pesticides Seed TraitsYield & ABSTPlant DiseaseInsect ControlGenome Editing BiomicaHuman Microbiome based Therapeutics Sep 2017 - Onward EvofuelCastor Seeds (100%) (90%)

Corporate Structure 8 Evogene Computational Predictive Platform Ag Divisions Seeds Biologicals Chemicals Evofuel Biomica

Corporate Structure 9 Evogene Computational Predictive Platform Ag Divisions Seeds Biologicals Chemicals Evofuel Biomica

Evogene’s Unique Product Development Approach 10 criterion A Numerous criteria nowadays have made traditional linear methodology inefficient Evogene takes product criteria into account at Stage Zerofocusing only on optimal product candidates criterion F criterion E criterion D criterion C criterion B Increasing probability of successReducing time to marketReducing budget Product Definition Successful Product Launch

‘Connecting the Dots’ 11 Evogene has created an integrated technological predictive platform that combines deep biological understanding with cutting-edge computational technology

‘Connecting the Dots’ 12 The platform includes intelligent algorithms that integrate and analyze vast data within the eco-systems, predicting cross dimensional interactions within a multi-dimensional space this is what we refer to as - ‘Connecting the Dots’ Evogene has created an integrated technological predictive platform that combines deep biological understanding with cutting-edge computational technology

Example of ‘Connecting the Dots’ for Novel Herbicides 13 Chemistry Biology Delivery / Application Chemoinformatics Novelty Diversity Tox. Synthetability Structure prediction Energy calculation Druggability Selectivity Safety Resistance Structure based design Mobility Phytotoxicity Metabolism Absorbance Formulation MD simulations Docking Binding mode Eco-Tox. Stability Ligand based design

Computational Predictive Biology (CPB) Platform Interconnected data hub Science: unique multidisciplinary scientific approach Tailored big data Analysis platforms using machine learning/AI to identify candidates Chemical discovery Stack discovery Target discovery Gene discovery Gene optimization Toxin discovery Microbial Discover/ Optimization Driving Innovation ‘Connecting the Dots’ 150K 20K 150K 15K

15 Validation and Development System

Partnerships Through the Years 16

Corporate Structure 17 Evogene Computational Predictive Platform Ag Divisions Seeds Biologicals Chemicals Evofuel Biomica

Product Selection Considerations 18 Large market opportunity and clear need for innovationThe major industry roadblock to developing innovative products is the need to ‘Connect the Dots’There is a clear path and reasonable time to commercialization and /or well-recognized value enhancing milestones during development period Leveraging on existing assets accumulated over the years to be able to form collaborations at an advanced stage of product development and at better financial termsContinuing work with partners on existing product programs, advancing discoveries in partners’ pipelines to re-focus initial discovery outputs to more downstream potential product offeringsEffective new products will contribute to human well-being

Corporate Structure 19 Evogene Computational Predictive Platform Ag Divisions Seeds Biologicals Chemicals Evofuel Biomica

20 Yield and environmental stress - potential to increase yield and plant adaptability to environmental stressDisease resistance – limited seed trait solutionsInsect control - overcome insect resistance to available commercial solutions Ag-Seeds - $37B1 (2015) Ag SeedsBiotechnology Seeds & Genomic Edited Seeds Source: Phillips McDougall Seed trait Safety Product Environment Stability Efficacy Ag Seeds – Market, Need & ‘Connecting the Dots’ ‘Connecting the Dots’

21 Collaboration Example - Monsanto Improvedseeds Gene discovery and trait optimization Development and commercialization Model plant validation Target plant validationand development CPB Collaboration period - 10 yearsObjective - improved seeds via biotechnologyCrops - corn, soybean, cotton, canolaTraits - Yield, drought tolerance, fertilizer utilizationDisease resistance – Fusarium resistance in corn Key terms - R&D and up-front payments - total ~$68MMilestone payments + royalties from sales$30M equity investment (including $12M in IPO)

Genome Editing – New Promising Technology Novel method for improving seed traitsResulting products may be considered Non-GMO with shorter time to marketMajor opportunity for all crops and locations 22 Evogene’s unique advantage – ‘What to edit’ Technological capabilities, knowledge and proprietary plant genomics big data, allow the identification of required edit-targets for crop improvement

Genome Editing – Product Development Impact 23 Discovery Phase I/POC Phase IIEarly Development Phase IIIAdvanced Development & Regulatory 18-24 months 4-6 years 2-4 years 1-2 years 8-16 years Discovery / POC Phase II Field testing Phase I Creation of edits Phase IIISeed production 12-24 months 6-12 months 12-24 months 12—36 months 5-8 years Conventional GM route*: New Genome Editing non GM route**: Non GMO approval could be given at this stage * Further details can be found in Evogene’s 20-F filing, pg. 36** According to industry estimates

Corporate Structure 24 Evogene Computational Predictive Platform Ag Divisions Seeds Biologicals Chemicals Evofuel Biomica

Ag-Biologicals – Market, Need &‘Connecting the Dots’ 25 Expected to reach $9B in 2020Short time to market – according to industry estimates may take only 5 years from initial work to market, depending on regulation. Reduced development costsNeed for novel solutions with stable performanceMicrobiome a promising source for innovation, now accessible via maturing technologiesIndustry leaders getting in on the action Ag-Biologicals - $3B1 (2014) Ag BiologicalsBio-stimulants & Bio-Pesticides Source: Phillips McDougall ‘Connecting the Dots’ Plant Pest Microbiome(plant/ pest)

Collaboration Example - DuPont-Pioneer Initiated in 2017Objective - Develop and commercialize microbiome based bio-stimulant products that improve corn yieldCurrent stage - Early developmentActivities -Evogene and DuPont-Pioneer to further develop candidate products in target regions in the USDuPont-Pioneer to commercialize products through its world-leading seed treatment business 26 Pre-commercialization Developmentstage 2 Development stage 1 Discovery Early development

27 Internal Program ExamplePositive results in corn & wheat field bio-stimulants programs Upcoming milestone: conclusion of 2017 results and nomination of microbial teams for 2018 trials in US Improved vigor and biomass resulted with >15% increase in spikelet weight and yield per plant EVM6810005 Non-inoculated Improved ear size and weight at harvest resulted with 17% increase of yield per plant EVM6810005 Main ears at harvest Main ears at harvest Non - inoculated (p < 0.05) (p < 0.1)

Corporate Structure 28 Evogene Computational Predictive Platform Ag Divisions Seeds Biologicals Chemicals Evofuel Biomica

‘Connecting the Dots’ Ag-Chemicals – Market, Need & ‘Connecting the Dots’ 29 Crop protection Ag-chemicals responsible for ~50% of key crops yieldIncreasing pest resistance to existing products creates a strong need for novel Ag-chemicals Ag-Chemicals - $50B1 (2015) Source: Phillips McDougall Ag ChemicalsHerbicides & Insecticides Chemistry Biology Delivery / Application Chemoinformatics Novelty Diversity Tox. Synthetability Structure prediction Energy calculation Drugability Selectivity Safety Resistance Structure based design Absorbance MD simulations Docking Binding mode Eco-Tox. Formulation Stability Ligand based design Mobility Phytotoxicity Metabolism

Collaboration Example - BASF Initiated in 2015, collaboration period - 3 yearsObjective - Herbicides with new MOA Discovery stageActivities:Evogene to identify novel targets and target-linked chemical candidatesBASF to screen & validate the chemical candidates and further develop successful candidates towards commercial products InnovativeHerbicide Chemical screens Target and chemical candidates discovery Screening, development and commercialization CPB Targets &chemicals Chemicalhits Development,regulation& registration 30

Ag-Chemicals Internal Pipeline 31 Discovery Pre-development Development & registration 2-3 years 3-4 years 3-4 years Target Target identification ComputationalScreen Hit Validation Hit-to-Lead Lead optimization Herbicides Targets I-VII Target VIII New targets Insecticides Target I Targets II-IV >10 Hits computationally linked to new targets AI optimization 5 targets AI optimization New SoAs Upcoming milestone – Initial Leadsefficacy improvement through optimization and target biological proof

Corporate Structure 32 Evogene Computational Predictive Platform Ag Divisions Seeds Biologicals Chemicals Evofuel Biomica

Evofuel 33 Genomics & Technology- advanced breeding and varietiesSeed production- Castor bean fields for the production of seedsAgro-technical support- Market specific crop protocolsMechanical harvesting solution support Providing farmers with the most advanced castor seeds & ag-service solutions Source: Grand View Research, August 2016, http://www.grandviewresearch.com/industry-analysis/castor-oil-derivatives-industry**http://www.grandviewresearch.com/press-release/global-castor-oil-derivatives-industry The global castor oil and derivatives market is expected to reach USD 2.30 billion by 2024**

Evofuel Global Footprints 34 Target: fully integrated chain – seed to oil Target: fully integrated chain – seed to oil Field trials – adapting to local conditions(Dom. Rep.) Pre-Commercial field trials Casa

Corporate Structure 35 Evogene Computational Prediction Platform Ag Divisions Seeds Biologicals Chemicals Evofuel Biomica

Biomica 36 Sources: BCC Research (2017) – Human Microbiome-based Drugs and Diagnostics MarketSVB – Emerging Healthcare: Microbiome Investment Trends Aug 2017) Discovery and development of human microbiome based therapeutics utilizing computational predictive biology (CPB) platform Strong scientific correlation between human microbiome and a wide range of diseasesMicrobiome-based therapeutics may complement existing therapies in treating known diseases ~$ 10Bn market opportunity by 2024$840M invested in microbiome space since 2010 Big pharma and VCs deeply engaged

Biomica – ‘Connecting the Dots’ 37 Candidates in silico Bacterial Strains Bacterial functions Host genomics Host clinical data Evogene’s computational platform enables multi-layer analysis to support the discovery of highly efficacious therapeutic candidates and relevant microbiome-based biomarkers Multi-layer analysis in support of discovery of efficacious therapeutic candidates and disease biomarkers

Corporate Structure 38 Evogene Computational Predictive Platform Ag Divisions Seeds Biologicals Chemicals Evofuel Biomica

Evogene Highlights 5 2 3 4 Strong balance sheet 1 Engine for next generation product for life science - targeting multi-billion dollar markets Unique technology platform (CPB), combining expertise in life science and cutting-edge computational technology – ‘Connecting the Dots’ Diversified product portfolio with clear paths to milestone payments and royalties Innovation partner-of-choice for industry leaders 39

Thank You Contact:investors@evogene.comT: +972 8 931 1934

41 Appendix - Financials

Key Financials – Balance Sheet 42 Thousand US $ 30.6.2017 31.12.2016 Current Assets 81,821 89,490 Long-Term Assets 5,625 6,496 Total Assets 87,446 95,986 Current Liabilities 4,633 5,225 Long-Term Liabilities 3,478 3,472 Shareholders Equity 79,335 87,289 Total Liabilities 87,446 95,986 Key Points: Cash position: 80 million USD as of 30.6.2017 No debtEstimated net cash usage for 2017: $16-$18 million

Key Financials – P&L 43 Thousand US $ H1 2017 H1 2016 2016 Revenues 1,899 3,824 6,540 Gross Profit 234 734 901 Operating Loss (10,426) (9,765) (21,089) Net Loss (9,590) (7,835) (19,592) Key Points: Revenues consist primarily of R&D revenues, reflecting cost reimbursement under our collaboration agreementsAdvancement of our collaboration agreement with Monsanto reducing R&D revenues